CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety. Journal of Medical Sciences, [S. l.], v. 21, n. 2, p. 30–35, 2026. DOI: 10.51984/szn7cg42. Disponível em: https://sebhau.edu.ly/journal/joms/article/view/4892. Acesso em: 24 sep. 2026.